Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.
about
Novel agents for advanced pancreatic cancerSpecificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancerTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTherapeutic potential of targeting acinar cell reprogramming in pancreatic cancerCurrent and future systemic treatment options in metastatic pancreatic cancer.Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future.Phase II clinical trials on investigational drugs for the treatment of pancreatic cancersOptimum chemotherapy in the management of metastatic pancreatic cancerImproving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.Emerging antibodies for the treatment of pancreatic cancer.Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model.Thapsigargin induces apoptosis of prostate cancer through cofilin-1 and paxillin.
P2860
Q26787087-7C0D279A-4E56-4357-8AFE-E2208733F9E6Q26853171-AAD3D875-9AF4-4D79-BE9E-914902CE8341Q26993238-F4D1B478-4BFC-41DD-AED4-CE59DA241F27Q28068998-43037B18-DA28-4089-BE41-F3D3CFC0270EQ33948033-3AE8AF38-E155-42B5-9A52-CBFCF6A4793EQ34127857-0C6EBD06-333C-49BA-883B-A4F53313BDBDQ34729692-71577A18-4095-4DFD-8BAA-3FA49E038674Q35604577-959D1CF9-BF7A-4311-9AAF-15330DAFAF3BQ36384541-6946A499-B7B3-475E-9566-CCACECFEFCBBQ37617976-94A4EB09-5DBC-4656-879B-67891486F19BQ38719148-7DFF3478-5323-4951-89D1-C817B9F2B2B1Q39158427-68E4818D-82D4-4E16-83DC-A34A66DA7D34Q41551352-FA65E01B-A889-4158-A8D2-323CE5699DA2Q55322285-5289BED9-FA51-4A28-B760-CDE2D0731375Q55646216-02C21421-7335-4297-BF0B-4E8160BC0E01
P2860
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Global, multicenter, randomize ...... metastatic pancreatic cancer.
@en
Global, multicenter, randomize ...... metastatic pancreatic cancer.
@nl
type
label
Global, multicenter, randomize ...... metastatic pancreatic cancer.
@en
Global, multicenter, randomize ...... metastatic pancreatic cancer.
@nl
prefLabel
Global, multicenter, randomize ...... metastatic pancreatic cancer.
@en
Global, multicenter, randomize ...... metastatic pancreatic cancer.
@nl
P2093
P2860
P356
P1433
P1476
Global, multicenter, randomize ...... , metastatic pancreatic cancer
@en
P2093
A Hartford
B M Wolpin
C M Rocha-Lima
E McWhirter
J Spratlin
K Morrison
P2860
P304
P356
10.1093/ANNONC/MDT066
P577
2013-02-28T00:00:00Z